Skip to main content
Top
Published in: BMC Neurology 1/2022

Open Access 01-12-2022 | Mefloquine | Case report

JC virus-induced progressive multifocal leukoencephalopathy in a presumably healthy patient

Authors: Xiang Wang, Jinxiu Chen, Jing Gong, Ying Wu, Xiang-hao Liu

Published in: BMC Neurology | Issue 1/2022

Login to get access

Abstract

Background

JC virus (JCV) is common among healthy individuals and remains latent but may be reactivated under immunosuppressive conditions, resulting in progressive multifocal leukoencephalopathy (PML). Here, we present a rare case of PML caused by JC virus infection in a previously healthy and immunocompetent patient.

Case presentation

A 67-year-old female without any disease history was admitted after presenting with rapidly progressive dementia. The preoperative diagnosis was progressive multifocal leukoencephalopathy, and corticosteroid treatment did not improve the symptoms. Brain lesions were surgically sampled, and JCV infection was confirmed by high-throughput DNA gene detection. This patient received a combined treatment of mirtazapine, mefloquine, and traditional Chinese herbs, and had stabilization of the disease on followed-up.

Conclusions

Although it is a rare, this case demonstrates that JC virus infection within the brain occurs in apparently healthy people. This case may increase our understanding of virus infection when facing the coronavirus epidemic in recent years, considering that similar medications were used.

Graphical Abstract

Literature
1.
go back to reference Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry. 2010;81(11):1288–91.CrossRef Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry. 2010;81(11):1288–91.CrossRef
2.
go back to reference Christakis PG, Okin D, Huttner AJ, Baehring JM. Progressive multifocal leukoencephalopathy in an immunocompetent patient. J Neurol Sci. 2013;326(1–2):107–10.CrossRef Christakis PG, Okin D, Huttner AJ, Baehring JM. Progressive multifocal leukoencephalopathy in an immunocompetent patient. J Neurol Sci. 2013;326(1–2):107–10.CrossRef
3.
go back to reference Long Y, Zhang Y, Gong Y, et al. Diagnosis of sepsis with cell-free DNA by Next-Generation sequencing technology in ICU patients. Arch Med Res. 2016;47(5):365–71.CrossRef Long Y, Zhang Y, Gong Y, et al. Diagnosis of sepsis with cell-free DNA by Next-Generation sequencing technology in ICU patients. Arch Med Res. 2016;47(5):365–71.CrossRef
4.
go back to reference Ferenczy MW, Marshall LJ, Nelson CD, et al. Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced demyelinating disease of the human brain. Clin Microbiol. 2012;Rev 25(3):471–506.CrossRef Ferenczy MW, Marshall LJ, Nelson CD, et al. Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced demyelinating disease of the human brain. Clin Microbiol. 2012;Rev 25(3):471–506.CrossRef
5.
go back to reference Hamaguchi M, Suzuki K, Fujita H, et al. Successful treatment of non-HIV progressive multifocal leukoencephalopathy: case report and literature review. J Neurol. 2020;267(3):731–8.CrossRef Hamaguchi M, Suzuki K, Fujita H, et al. Successful treatment of non-HIV progressive multifocal leukoencephalopathy: case report and literature review. J Neurol. 2020;267(3):731–8.CrossRef
6.
go back to reference Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother. 2009;53:1840–9.CrossRef Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother. 2009;53:1840–9.CrossRef
7.
go back to reference Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2019;380(17):1597–605.CrossRef Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2019;380(17):1597–605.CrossRef
8.
go back to reference Wicklein R, Heidegger S, Verbeek M, et al. Combined Treatment with Pembrolizumab and Allogenic BK Virus-Specific T cells in Progressive Multifocal Leukoencephalopathy: a Case Report. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1042.CrossRef Wicklein R, Heidegger S, Verbeek M, et al. Combined Treatment with Pembrolizumab and Allogenic BK Virus-Specific T cells in Progressive Multifocal Leukoencephalopathy: a Case Report. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1042.CrossRef
9.
go back to reference Cortese I, Beck ES, Al-Louzi O, et al. BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. Lancet Neurol. 2021;20(8):639–52.CrossRef Cortese I, Beck ES, Al-Louzi O, et al. BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. Lancet Neurol. 2021;20(8):639–52.CrossRef
Metadata
Title
JC virus-induced progressive multifocal leukoencephalopathy in a presumably healthy patient
Authors
Xiang Wang
Jinxiu Chen
Jing Gong
Ying Wu
Xiang-hao Liu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-022-03004-6

Other articles of this Issue 1/2022

BMC Neurology 1/2022 Go to the issue